GLP-1 weight loss results in women over 40: what the scale actually shows

What did @sandy__pedersen actually say?

Sandy's 12-week update is mostly testimonial territory, not medical advice, and that matters for how you read it. She says her experience has been "frickin fantastic," that she has had "no negative side effects," and that she credits this partly to prior healthy habits and "high quality supplements." She's careful to frame the medication as a tool, not a shortcut, which is actually a responsible framing most creators skip entirely.

What she does not do: name her specific medication, disclose her dose, or describe what the "high quality supplements" actually are. Those omissions matter, because the specifics drive the science. Her account is experiential and broadly positive, with one claim, the supplement theory, that deserves real scrutiny.

Does the science back this up?

The part about reduced food noise is well-supported. The no-side-effects claim is plausible but statistically unusual, and the supplement credit is speculative at best.

The sensation Sandy describes, thinking less obsessively about food, maps onto what researchers call the "cognitive offloading" effect of GLP-1 receptor agonists. Blundell et al. (2017, Diabetes, Obesity and Metabolism) documented significant reductions in food preoccupation and eating-related anxiety in patients on liraglutide. More recent semaglutide data from the STEP trials (Wilding et al., 2021, NEJM) confirmed meaningful appetite and craving suppression beyond simple calorie restriction. So yes, feeling like "a normal human" around food is a documented pharmacological effect, not a placebo.

On side effects: the SCALE and STEP trial data show nausea rates of 30-44% in semaglutide users and 15-20% for liraglutide. Experiencing none of these is possible, but it puts Sandy in a minority cohort. Prior healthy habits and slower titration schedules can reduce GI burden, which is a real mechanism, but there is no controlled evidence that pre-existing wellness habits eliminate side effect risk categorically.

What did they get wrong (or right)?

Sandy gets the framing right and one mechanism claim wrong. Credit where it is due: calling GLP-1 medication "a tool" rather than a cure, and stating explicitly "this is not a ticket for me to just do whatever I want," is more grounded than the majority of weight-loss content on this platform. That framing reflects clinical guidance accurately.

Where she goes off track: attributing her lack of side effects to "high quality supplements that help support the GLP-1 journey" is not supported by evidence. There is no peer-reviewed data showing that any supplement stack reduces GLP-1 side effects in otherwise healthy adults. This kind of claim, even when framed casually, can drive supplement purchases based on false inference. The more likely explanation for her tolerability is individual pharmacokinetic variation, slower dose titration, or baseline GI health, none of which are supplement-dependent. She is not lying, she is just giving her supplements credit they have not earned in the literature.

What should you actually know?

GLP-1 medications work for a meaningful percentage of people, but the experience varies more than social media suggests. Sandy's smooth 12 weeks is real but not representative.

First, the population matters. Women in perimenopause face overlapping hormonal shifts that can independently affect appetite, weight distribution, and mood. Joffe et al. (2020, Menopause) found that estrogen decline alters GLP-1 receptor sensitivity in some patients, meaning perimenopause-era users may respond differently than younger populations. That is a reason to discuss expectations carefully with a prescriber, not to assume Sandy's trajectory will be yours.

Second, 12 weeks is a short window. The STEP 1 trial ran 68 weeks for a reason. Long-term tolerability data, plateau periods, and muscle mass preservation questions only emerge over time. Early enthusiasm is common. What happens at month six or twelve is a different story, and one creators rarely follow up on.

Third, the supplement industry around GLP-1 is growing fast and running well ahead of the evidence. Buyer skepticism is warranted.

Bottom line on this video

Sandy's update is honest about her personal experience and responsible in its framing. The food-noise reduction she describes is pharmacologically real. The supplement attribution is soft speculation dressed as a contributing factor. And her results, while genuinely positive, reflect one data point on a wide distribution of outcomes. Watch creator content like this as motivation if it helps, but pressure-test the mechanistic claims before acting on them.